

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 555-88

C# M#

COUKOS et al.

TC/A.U.

#2CT  
127 Rec'd PCT/PTO 13 JAN 2006

Serial No. 10/525,643

Examiner:

Filed: (Requires Completion)

Date: January 13, 2006

Title: IMMUNE CELL RECEPTOR LIGAND AND IMMUNE CELL RECEPTOR

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$50.00 \$0.00 (1202)/\$0.00 (2202) \$

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$200.00 \$0.00 (1201)/\$0.00 (2201) \$

If proper multiple dependent claims now added for first time, (ignore improper); add  
\$360.00 (1051)/\$180.00 (2051) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s)  
One Month Extension \$120.00 (1251)/\$60.00 (2251)  
Two Month Extensions \$450.00 (1252)/\$225.00 (2252)  
Three Month Extensions \$1020.00 (1253)/\$510.00 (2253)  
Four Month Extensions \$1590.00 (1254)/\$795.00 (2254)  
Five Month Extensions \$2160.00 (1255)/\$1080.00 (2255) \$

Terminal disclaimer enclosed, add \$130.00 (1814)/ \$65.00 (2814) \$

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee \$180.00 (1806) \$

Assignment Recording Fee \$40.00 (8021) \$


Other: \$

**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor  
Arlington, Virginia 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
MJW:tatNIXON & VANDERHYE P.C.  
By Atty: Mary J. Wilson, Reg. No. 32,955Signature: Mary J. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

Confirmation No. 7985

COUKOS et al.

Atty. Ref.: 555-88

Serial No. 10/525,643

Group: unknown

Filed: (Requires Completion)

Examiner: Unknown

For: IMMUNE CELL RECEPTOR LIGAND AND IMMUNE CELL RECEPTOR

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

January 13, 2006

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☒ 1. **PTO/SB/08a Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO/SB/08a together with copies (as  
may be required) of each identified document and a translation or a  
concise explanation of each non-English language document (such  
as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

COUKOS et al.  
Serial No. 10/525,643

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: Mary J. Wilson  
Mary J. Wilson  
Reg. No. 32,955

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

555-88

10/525,643

APPLICANT

COUKOS et al.

(Use several sheets if necessary)

FILING DATE

GROUP

(Requires Completion)

unknown

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,458,350	10/2002	Cosman et al			
	5,763,218	6/1998	Fujii et al			
	20020187151	12/2002	Raulet et al			
	20030147847	8/2003	Cosman et al			

**FOREIGN PATENT DOCUMENTS**

							ENGLISH ABSTRACT	
DOCUMENT			DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
		WO 01/83545	11/2001	Japan			X	
		WO 98/04585	2/1998	WIPO				
		WO 02/051863	4/2002	WIPO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	N_Geneseq Accession #AAG68335, 2 February 2001
	N_Geneseq Accession #AAW40215, 07 July 1998
	GenEmbl Accession #AL355312, 09 March 2001
	Maniatis et al, "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, pgs. 51-54 (1982)
	Liebowitz et al, "Costimulatory approaches to adoptive immunotherapy", Curr. Opin. Oncol. 10(6):533-541 (1998) - Abstract
	Zhang et al, "Novel human C-type lectin superfamily member CLL-1", Unpublished, PRI 26-MAR-2002, Accession No. AF24788 - Abstract
	Radosavljevic et al, "A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3", Genomics 79(1):114-123 (2002), PRI 12-FEB-2002, Accession No. AF359243 - Abstract
	Lanier and Cerwenka, "Homo sapiens RAE-1-like transcript 4 (RL-4) mRNA", Unpublished, PRI 09-OCT-2001, Accession No. AY054974 - Abstract
	Chalupny et al, "ULBP4 is a novel ligand for human NKG2D", Biochemical and Biophysical Research Communication 305:129-135 (2003)
	Maus et al, "Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB", Nature Biotechnology 20:143-148 (2002)
	Conejo-Garcia et al, "Lethal, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells", Cancer Biology & Therapy 2(4):e112-e117 (2003)

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO/SB/08a)